Loading clinical trials...

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy | Clinical Trials | Clareo Health

COMPLETEDPHASE1/PHASE2

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Safety, Immunogenicity and Clinical Efficacy of an Allergen Vaccine (AllQbG10) in Subjects With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

NCT00652223•Cytos Biotechnology AG

View on ClinicalTrials.gov

Summary

The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.

Eligibility

Age

18 - 55 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites
•Mild asthma
•Females only if non-reproductive or agree to practice an effective and accepted method of contraception

Exclusion Criteria

•Relevant cardiovascular, renal, pulmonary or endocrine disease
•History of autoimmune disease
•Severe allergies
•History of active infectious disease
•Current diagnosis or history of malignancy
•Relevant neurological or psychiatric disorder
•Pregnancy or lactation
•History of alcohol abuse or other recreational drugs
•Use of an investigational drug within three month before enrolment
•Blood donation within 30 days before enrolment

Locations (1)

University Hospital Zurich, Department of Dermatology

Zurich, Canton of Zurich, Switzerland

Key Dates

Start Date

March 1, 2005

Completion Date

November 1, 2005

Last Updated

April 9, 2008

Enrollment

ACTUAL participants

Conditions

Perennial Allergic RhinoconjunctivitisAllergic Asthma

Interventions

CYT005-AllQbG10

BIOLOGICAL

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

NCT05008965

Allergic Asthma

View study

RECRUITINGPHASE3

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

NCT04699604

Allergic Asthma

View study

ENROLLING_BY_INVITATIONEARLY_PHASE1

Asthma Inflammation Research

NCT01536522

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 9, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy

Inclusion Criteria

Exclusion Criteria

Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma

A Histamine Pharmacodynamic Biomarker to Guide Treatment in Pediatric Asthma (HAS3)

Asthma Inflammation Research

Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis

Tyrosine Allergoid Paediatric and Adult Study

Trial of JYB1904 in Patients With Allergic Asthma